Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
Status:
Terminated
Trial end date:
2017-03-20
Target enrollment:
Participant gender:
Summary
RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy
using leuprolide and flutamide may fight prostate cancer by reducing the production of
testosterone. It is not yet known whether receiving leuprolide and flutamide is more
effective than receiving no further therapy.
PURPOSE: Randomized phase III trial to determine the effectiveness of hormone therapy in
treating patients who have stage I or stage II prostate cancer that is at high risk of
recurrence and who have already undergone surgery.
Phase:
Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
AstraZeneca Eastern Cooperative Oncology Group National Cancer Institute (NCI)